Albireo Pharma Inc Capitalización de mercado
¿Qué es el Capitalización de mercado de Albireo Pharma Inc?
El Capitalización de mercado de Albireo Pharma Inc es $492.28M
¿Cuál es la definición de Capitalización de mercado ?
La capitalización de mercado es el valor de mercado en un momento en el tiempo de las acciones en circulación de una empresa que cotiza en bolsa, que es igual al precio de la acción en ese punto de tiempo por el número de acciones en circulación .
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
Capitalización de mercado de compañías en Sector Health Care en NASDAQ en comparadas con Albireo Pharma Inc
¿Qué hace Albireo Pharma Inc?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Empresas con capitalización de mercado similar a Albireo Pharma Inc
- NOCIL tiene Capitalización de mercado de $491.44M
- Nektar Therapeutics tiene Capitalización de mercado de $491.50M
- Tejon Ranch Co tiene Capitalización de mercado de $491.61M
- Sisram Medical Ltd tiene Capitalización de mercado de $491.70M
- enCore tiene Capitalización de mercado de $491.81M
- Garrett Motion Inc tiene Capitalización de mercado de $491.97M
- Albireo Pharma Inc tiene Capitalización de mercado de $492.28M
- Brasilagro Companhia Brasileira De Propriedade Agricola tiene Capitalización de mercado de $492.33M
- Premier Gold Mines tiene Capitalización de mercado de $493.21M
- Beijing Enterprises Clean tiene Capitalización de mercado de $493.64M
- Xinyuan Ppty Mgmt Svc tiene Capitalización de mercado de $493.73M
- IQE Plc tiene Capitalización de mercado de $494.04M
- South Plains Inc tiene Capitalización de mercado de $494.72M